Agios Pharmaceuticals (AGIO) FCF Margin (2012 - 2026)
Agios Pharmaceuticals' (AGIO) quarterly FCF Margin came in at 130.79% in Q2 2026, up 49545.0% YoY from N/an in Q2 2025, and up 77.33% on a QoQ basis from 576.93% in Q1 2026.
Powered by 
Analysis
Agios Pharmaceuticals (AGIO) FCF Margin (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals (AGIO) has 14 years of FCF Margin data on file, last reported at 130.79% in Q2 2026.
- Quarterly FCF Margin rose 49545.0% year-over-year to 130.79% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 371.43% (up 62925.0% YoY) and the FY2025 annual result came in at 698.33%, up 37440.0% from the prior year.
- FCF Margin improved to 130.79% in Q2 2026, from 576.93% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 130.79% in Q2 2026 to a low of 12084.01% in Q1 2022.
- A 5-year average of 1646.73% and a median of 1009.12% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin jumped 1037993 bps — and 2024, when it plunged 22626 bps.
- Tracing AGIO's FCF Margin over 5 years: stood at 1537.73% in 2022, then surged by 33 bps to 1023.82% in 2023, then slipped by 22 bps to 1250.08% in 2024, then soared by 61 bps to 487.47% in 2025, then soared by 73 bps to 130.79% in 2026.
- The last three FCF Margin figures came in at 130.79% (Q2 2026), 576.93% (Q1 2026), and 487.47% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 70.82% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -22.35% |
| 10 | Agios Pharmaceuticals | 1.97 Bn | 1.97 Bn | 41.75 Mn | -130.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -130.79% |
| Mar 31, 2026 | -576.93% |
| Dec 31, 2025 | -487.47% |
| Sep 30, 2025 | -696.48% |
| Jun 30, 2025 | -626.25% |
| Mar 31, 2025 | -1,286.44% |
| Dec 31, 2024 | -1,250.08% |
| Sep 30, 2024 | -944.19% |
| Jun 30, 2024 | -844.42% |
| Mar 31, 2024 | -1,221.25% |
| Dec 31, 2023 | -1,023.82% |
| Sep 30, 2023 | -838.11% |
| Jun 30, 2023 | -994.41% |
| Mar 31, 2023 | -1,704.08% |
| Dec 31, 2022 | -1,537.73% |
| Sep 30, 2022 | -2,030.40% |
| Jun 30, 2022 | -1,364.30% |
| Mar 31, 2022 | -12,084.01% |
| Dec 31, 2020 | -113.43% |
| Sep 30, 2020 | -211.52% |